new BindingDB logo
myBDB logout

8 articles for thisTarget

The following articles (labelled with PubMed ID or TBD) are for your review
PMIDDataArticle TitleOrganization
24900372 60 Discovery of SCH 900271, a Potent Nicotinic Acid Receptor Agonist for the Treatment of Dyslipidemia.EBI TBA
12930155 20 Pyrazole derivatives as partial agonists for the nicotinic acid receptor.EBI Leiden/Amsterdam Center for Drug Research
22209457 47 SAR studies of C2 ethers of 2H-pyrano[2,3-d]pyrimidine-2,4,7(1H,3H)-triones as nicotinic acid receptor (NAR) agonist.EBI Merck Research Laboratory
24900295 61 Discovery of a Potent Nicotinic Acid Receptor Agonist for the Treatment of DyslipidemiaEBI TBA
20724150 51 Pyrido pyrimidinones as selective agonists of the high affinity niacin receptor GPR109A: optimization of in vitro activity.EBI F. Hoffmann-La Roche Ltd
20184326 40 Discovery of a biaryl cyclohexene carboxylic acid (MK-6892): a potent and selective high affinity niacin receptor full agonist with reduced flushing profiles in animals as a preclinical candidate.EBI Merck Research Laboratories
19309152 81 Discovery of novel tricyclic full agonists for the G-protein-coupled niacin receptor 109A with minimized flushing in rats.EBI Merck Research Laboratories
18665582 12 3-(1H-tetrazol-5-yl)-1,4,5,6-tetrahydro-cyclopentapyrazole (MK-0354): a partial agonist of the nicotinic acid receptor, G-protein coupled receptor 109a, with antilipolytic but no vasodilatory activity in mice.EBI Arena Pharmaceuticals